All In Biotech

Company · ALNY

Alnylam Pharmaceuticals

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Alnylam Pharmaceuticals.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

4

4 still marketed

Novel approvals

4

Approvals since 2021

4

Originals and new uses

Phase 3 trials

15

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Amvuttra new use Priority reviewOrphanMar 20, 2025
  • Onpattro new use OrphanJan 13, 2023
  • Oxlumo new use OrphanOct 6, 2022
  • Amvuttra approved NovelOrphanJun 13, 2022
  • Oxlumo approved NovelBreakthrough therapyPriority reviewOrphanNov 23, 2020
  • Givlaari approved NovelBreakthrough therapyPriority reviewOrphanNov 20, 2019
  • Onpattro approved NovelBreakthrough therapyPriority reviewOrphanAug 10, 2018

Drugs in development (6)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

Recruiting Phase 3 trials

Largest first.

Marketed drugs (4)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.